ESLA
Estrella Immunopharma Inc.
NASDAQ: ESLA · HEALTHCARE · BIOTECHNOLOGY
$1.64
+11.56% today
Updated 2026-04-30
Market cap
$67.41M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-0.35
Dividend yield
—
52W range
$1 – $3
Volume
0.1M
Estrella Immunopharma Inc. (ESLA) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| R&D | $457231.00 | $1.39M | $6.44M | $4.11M | $6.41M | $10.25M |
| SG&A | $276462.00 | $296248.00 | $442680.00 | $3.20M | $1.42M | $2.81M |
| Operating income | $-733693.00 | $-1.69M | $-1.57M | $-7.31M | $-8.85M | $-13.06M |
| Operating margin | — | — | — | — | — | — |
| EBITDA | $-733693.00 | $-1.69M | $-686971.00 | — | $-8.85M | $-13.06M |
| EBITDA margin | — | — | — | — | — | — |
| EBIT | $-733693.00 | $-1.69M | $-915456.00 | $-7.31M | $-8.81M | — |
| Interest expense | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-733693.00 | $-1.69M | $-996104.00 | $-7.31M | $-8.85M | $-13.06M |
| Net income growth (YoY) | — | -129.7% | +40.9% | -634.0% | -21.0% | -47.6% |
| Profit margin | — | — | — | — | — | — |